| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 20/01/2025 | 11:45 | PR Newswire (US) | Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CRBU | NASDAQ:CRBU | Caribou Biosciences Inc |
| 16/01/2025 | 11:45 | PR Newswire (US) | CRBU LAWSUIT ALERT: The Gross Law Firm Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:CRBU | Caribou Biosciences Inc |
| 13/01/2025 | 14:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CRBU | Caribou Biosciences Inc |
| 13/01/2025 | 11:45 | PR Newswire (US) | Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU | NASDAQ:CRBU | Caribou Biosciences Inc |
| 13/01/2025 | 01:05 | GlobeNewswire Inc. | Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 | NASDAQ:CRBU | Caribou Biosciences Inc |
| 10/01/2025 | 23:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CRBU | Caribou Biosciences Inc |
| 10/01/2025 | 22:55 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:CRBU | Caribou Biosciences Inc |
| 09/01/2025 | 11:45 | PR Newswire (US) | Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors - Contact The Gross Law Firm | NASDAQ:CRBU | Caribou Biosciences Inc |
| 07/01/2025 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:CRBU | Caribou Biosciences Inc |
| 06/01/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU | NASDAQ:CRBU | Caribou Biosciences Inc |
| 02/01/2025 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer | NASDAQ:CRBU | Caribou Biosciences Inc |
| 06/12/2024 | 22:06 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
| 20/11/2024 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences to Participate in Upcoming Investor Conferences | NASDAQ:CRBU | Caribou Biosciences Inc |
| 15/11/2024 | 00:08 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
| 06/11/2024 | 22:08 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CRBU | Caribou Biosciences Inc |
| 06/11/2024 | 22:05 | GlobeNewswire Inc. | Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
| 27/09/2024 | 22:02 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
| 25/09/2024 | 15:00 | GlobeNewswire Inc. | Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 | NASDAQ:CRBU | Caribou Biosciences Inc |
| 03/09/2024 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML | NASDAQ:CRBU | Caribou Biosciences Inc |
| 12/08/2024 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer | NASDAQ:CRBU | Caribou Biosciences Inc |
| 06/08/2024 | 22:05 | GlobeNewswire Inc. | Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
| 09/07/2024 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board | NASDAQ:CRBU | Caribou Biosciences Inc |
| 03/06/2024 | 01:00 | GlobeNewswire Inc. | Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:CRBU | Caribou Biosciences Inc |
| 30/05/2024 | 22:01 | GlobeNewswire Inc. | Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences | NASDAQ:CRBU | Caribou Biosciences Inc |
| 07/05/2024 | 22:05 | GlobeNewswire Inc. | Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
| 24/04/2024 | 16:00 | GlobeNewswire Inc. | Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:CRBU | Caribou Biosciences Inc |
| 15/04/2024 | 15:00 | GlobeNewswire Inc. | Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) | NASDAQ:CRBU | Caribou Biosciences Inc |
| 04/04/2024 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus | NASDAQ:CRBU | Caribou Biosciences Inc |
| 11/03/2024 | 22:08 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:CRBU | Caribou Biosciences Inc |
| 11/03/2024 | 21:25 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:CRBU | Caribou Biosciences Inc |